BACKGROUNDHIV infection has evolved into greatest pandemic in human history with more than 60 million humans currently affected by HIV virus. CD4 cell dysfunction is the hallmark of HIV disease. CD4 count is important for initiation and monitoring of ART and opportunistic infection prophylaxis, we have conducted a study on 100 HIV patients on HAART therapy whose CD4 count is < 350/MI, follows for 6 months.

BACKGROUND The incidence of CAD is increasing rapidly. Thrombolytic therapy revolutionised the treatment of acute STEMI. The efficacy, safety of Tenecteplase in STEMI is very much proved. The objective of this study is to study the efficacy and safety of tenecteplase in patients with ST elevated acute myocardial infarction. MATERIALS AND METHODS This is a retrospective observational study done in 100 patients from June 2016 to May 2017. RESULTS The overall rate of clinically successful thrombolysis (CST) by tenecteplase is 92%. The success rate of delayed administration (> 6 hours) was 84%. 92% had chest pain relief with a medium time of 15 minutes. ST segment resolution was observed in 94% patients. Reinfarction was observed in 3% of patients. Bleeding excluding ICH was observed in 2% of patients. 3 patients died before discharge. No hypotension was observed with tenecteplase. CONCLUSION Our study further reinforced the efficacy and safety of tenecteplase in patients presenting with STEMI including high risk subgroups. Our study confirms the importance of early thrombolysis in Indian Scenario.